ArmaGen (UCLA) Re-Engineers Erythropoietin for Stroke (11/5/2010)

ArmaGen provides platform technology solutions to the ‘blood-brain barrier’ problem. The company was founded in 2004 by Dr. William Pardridge, Professor of Medicine and Endocrinology at UCLA.

ArmaGen re-engineers erythropoietin for stroke. Erythropoietin (EPO) is a potent neuroprotective agent, which could be developed for treatment of acute stroke. However, EPO does not cross the blood-brain barrier (BBB), and the BBB is intact in the early hours after stroke when neuroprotection is still possible. AGT-115 is a re-engineered form of human EPO that crosses the BBB via receptor-mediated transport. EPO is fused to a genetically engineered monoclonal antibody (MAb) against the human insulin receptor (HIR). read more


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: